0
0
NEW DELHI — In a major crackdown aimed at preserving the integrity of healthcare delivery, the National Medical Commission (NMC) has issued an urgent directive to state medical councils across India. The apex medical regulatory body has ordered an expedited disciplinary inquiry into 30 doctors from nine states who were found guilty of accepting a luxury foreign trip to Paris and Monaco. The lavish junket, valued at ₹1.91 crore, was funded by AbbVie Healthcare India Pvt. Ltd., a prominent pharmaceutical firm, in direct violation of the Uniform Code of Pharmaceutical Marketing Practices (UCPMP).
The directive, sent via a stern reminder by the NMC’s Ethics and Medical Registration Board (EMRB), arrives amid mounting concerns over regulatory delays. Nearly six months after the names were initially distributed to regional councils for enforcement, six states have yet to submit their action-taken reports.
The Paris-Monaco Junket: Luxury Under the Guise of Education
The controversy stems from an anonymous complaint received by the Department of Pharmaceuticals (DoP) on May 24, 2024. A subsequent high-level government audit revealed that AbbVie Healthcare India—a subsidiary of the American pharmaceutical giant AbbVie Inc.—had fully sponsored upscale international travel and luxury accommodations for 30 healthcare professionals.
The trips took place between February and March 2024, ostensibly to allow the physicians to attend the Aesthetics & Anti-Aging Medicine World Congress in Monaco and a subsequent event in Paris. The invited specialists were all closely tied to the prescription and promotion of premium medical aesthetics, including blockbusters like Botox and the dermal filler Juvederm.
A geographic breakdown of the medical professionals implicated in the probe spans across nine states:
-
Maharashtra: 11 doctors
-
Gujarat: 3 doctors
-
Telangana: 3 doctors
-
Delhi: 2 doctors
-
Karnataka: 2 doctors
-
Punjab: 2 doctors
-
West Bengal: 2 doctors
-
Assam: 1 doctor
-
Kerala: 1 doctor
Despite the definitive findings of the government audit, administrative anomalies have slowed the disciplinary process. When the DoP forwarded the file to the NMC, three names were missing from the original roster of 30, with no official explanation provided for the omission. The remaining 27 names were sent to the respective state medical councils to initiate formal inquiries and implement appropriate punitive measures.
Strict Regs: Understanding the UCPMP 2024 Breach
The core of the legal and ethical violation rests upon the Uniform Code of Pharmaceutical Marketing Practices (UCPMP) 2024, which was formally implemented to curb deep-seated unethical marketing strategies. The code explicitly mandates that pharmaceutical companies are strictly accountable for the actions of their medical representatives and employees.
Under the provisions of the UCPMP, companies are entirely banned from offering gifts, monetary benefits, hospitality, or paid travel to medical practitioners or their family members.
The Continuing Medical Education (CME) Exception: The UCPMP permits corporate travel sponsorship or hotel accommodations only if the healthcare professional is attending an event as an officially designated, active speaker or presenter. Traditional attendance at a congress does not qualify.
Because the aesthetics congress trip featured extensive leisure itineraries, expensive fine dining, and premium resort stays without verified speaking roles for all attendees, the audit committee ruled the entire corporate layout as an illegal inducement designed to influence clinical prescribing patterns.
Bureaucratic Roadblocks: State Councils Fall Behind
The slow pace of accountability has drawn sharp criticism from healthcare watchdogs. By mid-June 2026, it will have been half a year since state councils received the data from the NMC. Despite this timeline, medical councils in Assam, Delhi, Karnataka, Kerala, Telangana, and West Bengal have failed to deliver conclusive disciplinary outcomes.
In defense of the timeline, officials from the Kerala State Medical Council noted that they received information regarding their sole implicated doctor on December 16, 2025. The council registry confirmed that a formal explanation has been demanded from the physician, but emphasized that the complex legal process remains underway.
According to provisions within the Indian Medical Council Act, state bodies are granted a maximum window of six months to adjudicate complaints of professional misconduct. If a regional council fails to act within this period, the NMC retains the statutory right to strip the state of jurisdiction and refer the case directly to its own central ethics committee.
“We forwarded these names for immediate inquiry and appropriate action because regional councils hold primary jurisdiction over professional misconduct,” stated Dr. Abhijat Sheth, Chairperson of the NMC. However, the regulatory body’s recent warning indicates that its patience with state-level stagnation is running thin.
The Prescription Ripple Effect: Why Freebies Harm Public Health
The intersection of luxury marketing and medicine introduces distinct risks to patient safety and financial well-being. When corporate gifts influence clinical decisions, the objective nature of medical care is compromised.
Public health research shows that unethical pharmaceutical promotion directly alters how physicians prescribe medications, frequently leading to:
-
The over-prescription of drugs: Recommending medications that are not strictly necessary for the patient’s recovery.
-
Elevated dosages: Prescribing higher strengths of a medicine when a lower, safer dose would suffice.
-
Extended timelines: Keeping patients on therapies for longer periods than clinically indicated.
-
Irrational drug combinations: Co-prescribing multiple brand-name drugs, which escalates costs and heightens the risk of adverse drug-to-drug interactions.
“The culture of freebies in pharmaceutical marketing destroys consumers’ trust in medicines and doctors,” cautioned Dr. KV Babu, an ophthalmologist and public health advocate whose Right to Information (RTI) applications systematically brought the details of this case into the public eye.
The phenomenon is globally recognized. A landmark study published in the Indian Journal of Medical Research evaluated the attitudes of medical graduates regarding industry practices. The data revealed that while younger doctors frequently recognized that expensive gifts unrelated to patient care were fundamentally unethical, many still routinely accepted lower-cost promotional items.
However, international data proves that even minor items carry weight. A comprehensive U.S. public health study established that small gifts and free meals significantly shifted doctor behavior. The research uncovered a direct link between concentrated pharmaceutical marketing, higher brand-name prescribing rates, and worst-case outcomes like increased opioid over-prescribing in targeted regions.
A Structural Blind Spot: Corporate Impunity vs. Doctor Suspension
As state medical councils scramble to address the NMC’s directive, the case highlights a glaring imbalance in India’s regulatory framework. Under current laws, a doctor found guilty of ethical misconduct faces severe personal penalties, including the temporary or permanent revocation of their medical license. Conversely, the pharmaceutical corporations that engineer and fund these multi-million rupee campaigns face highly limited statutory penalties under the UCPMP’s current self-regulatory structure.
The legal disparity has reached the highest level of judicial review. The Supreme Court of India is actively hearing a comprehensive petition filed by the Federation of Medical and Sales Representatives Associations of India. The lawsuit seeks the implementation of legally binding, statutory guidelines to govern pharmaceutical marketing, arguing that the voluntary nature of the UCPMP leaves critical loopholes open.
Historically, the Competition Commission of India (CCI) has attempted to curb market manipulation by penalizing unethical corporate alliances, levying fines worth ₹46.43 crore in 2018 and ₹74 crore in 2019 against companies that stifled market competition. Yet, public health experts argue that without criminal liability or massive financial penalties specifically targeting code violations, multinational firms may continue to view these infractions merely as a standard cost of doing business.
Transparency Red Flags: Hidden Names and Vanishing Roster Assets
Compounding the public health anxiety is a lack of institutional transparency. Despite two independent government-appointed committees validating that a gross violation occurred, both the Department of Pharmaceuticals and the NMC have strictly refused to publish the names of the doctors under investigation.
An RTI appeal escalated to the Prime Minister’s Office (PMO) succeeded in forcing the disclosure of the corporate entity involved (AbbVie), but the identities of the treating physicians remain hidden behind a wall of administrative confidentiality. Furthermore, federal authorities have completely ignored media queries regarding how three medical professionals mysteriously disappeared from the official disciplinary list between September and December 2025.
For the average healthcare consumer, this lack of transparency makes it impossible to verify if their own practitioner was among those taking luxury vacations sponsored by the manufacturers of the aesthetics products they are being prescribed.
Looking Ahead: The Looming Regulatory Deadline
The upcoming weeks mark a crucial turning point for medical accountability in India. With the six-month statutory deadline expiring on June 15, 2026, the NMC is poised to seize control of the files from non-compliant state councils.
Medical professionals found to have systematically violated Regulation 6.8 of the Medical Council Regulations face severe occupational penalties. Depending on the exact financial valuation of the benefits accepted, penalties can range from formal reprimands to multi-year suspensions from practicing medicine.
As the Supreme Court deliberates on turning the UCPMP into an enforceable law, the resolution of the Paris-Monaco junket case will serve as a definitive baseline for how strictly India intends to police the financial relationships between the pharmaceutical industry and the doctors holding the prescription pads.
Reference Section
- https://medicaldialogues.in/news/health/doctors/doctors-from-9-states-named-in-rs-19-crore-pharma-freebies-case-nmc-orders-medical-councils-to-expedite-action-172378
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
